No Data
No Data
Novartis Lifts Guidance After Profit, Sales Top Views
Novartis AG (NVS) Q1 2025 Earnings Call Transcript Summary
Swiss Stocks Advance; Cosmo Shares Fall on Acne Vulgaris Drug Setback
Novartis AG (NOVN) Gets a Hold From UBS
Bernstein Sticks to Their Buy Rating for Novartis AG (NOVN)
Correction to Novartis Market Talk
HH1000 : aren't they doing an offering. diluting shares. it's gonna make the price drop. no thanks for buying
Tonyco HH1000 :
DazzlerAus HH1000 : they are not necessarily doing an offering S3 expire it oretty standard for these conpanies to have a standing S3 in case its needed often it just insurance against an unexpected result ie if suddenly their main drug started resulting in bad side effects